Protocol Ledger

NCT04380142 · Phase III · COMPLETED

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Interventional Phase III clinical trial protocol NCT04380142 sponsored by AbbVie in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-19 Enrollment: 174 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04380142
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)174 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04380142
Protocol FieldVerified Registry Value
NCT IdentifierNCT04380142
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment174 participants (ACTUAL)
Registered Start Date2020-10-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI